MANAGING TYPE 2 DIABETES
INSULIN PUMP CANDIDATE 1 WITH TYPE 2 DIABETES
- 52 years old
- Type 2 diabetes for 8 years
- Overweight, with a BMI of 31
- On MDI regimen
- HbA1c of 9% (75mmol//mol) and TDD: 102 units.
To manage his type 2 diabetes, Mark requires large dose injections, which are often painful. He has a busy schedule and prefers to be discrete about his diabetes. As a result, he often forgets to inject his meal time doses which can result in hyperglycaemic events.
Mark would like to reduce the frequency of hyperglycaemic events and manage his diabetes better.
The MiniMed™ 640G insulin pump has a 3ml (300 units) reservoir which accommodates one infusion set insertion every 3 days and up to 75 units of bolus insulin, gradually delivered to the patient. Using the MiniMed™ insulin pump will ensure Mark adheres to his prescribed insulin regimen through continuous basal insulin and discreet bolusing. The missed meal bolus reminder feature will help Mark follow his mealtime insulin plan.
INSULIN PUMP CANDIDATE 2 WITH TYPE 2 DIABETES
- 55 years old. Has had Type 2 diabetes for 16 years
- Overweight, with a BMI of 32
- On MDI regimen
- HbA1c of 10.2% and TDD: 96 units
Catherine has Type 2 diabetes and is scared of injections as she finds them painful. She often skips injections to avoid the pain.
She would like to stay in good health for her family.
Users of the MiniMed™ 640G pump only have to perform an infusion set change every 2-3 days. This means that Catherine can limit the insulin injections to the infusion set change only, making it easier to manage her diabetes treatment. Using the MiniMed™ insulin pump will help Catherine adhere to her prescribed insulin regimen through continuous basal insulin and discreet bolusing. Plus, HbA1c reduction achieved on MiniMed™ pump therapy1 is associated with lower risk of long-term microvascular complications2,3, allowing her to achieve her goal by staying in good health for her family.
1Reznik Y. Cohen O. Aronson R. et al. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open label controlled trial. Lancet 2014 Volume 384, Issue 9950, P. 1265 - 1272, 4 October 2014
2UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853
3The post-trial monitoring results: 10 years follow up: Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10- year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359:1577-1589
INSULIN PUMP THERAPY (CSII)
Introducing patients to new technologies and clinical practices
SENSOR AUGMENTED PUMP THERAPY (SAP)
Incorporating Continuous Glucose Monitoring to reduce HbA1c and improved glycaemic control.
THE MINIMED™ 640G SYSTEM
Our most advanced insulin pump, with SmartGuard™ technology